Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
June 18, 2008

Gilead Sciences Taps Monogram Sciences for Resistance Testing in Elvitegravir Phase III Studies

  • Monogram Biosciences will provide resistance testing and consultative services for Gilead Science’s Elvitegravir Phase III studies. Monogram assays will be used to screen patients for study enrollment and help select drugs to be given in conjunction with Elvitegravir during the study.

    Both Monogram's Integrase phenotype and genotype assays were used in Elvitegravir preclinical and Phase II studies, and will be used to evaluate Phase III patient outcomes.

    Related Links:

    Sensitivity Enhancements to Monogram's Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy

    Gilead Targets HIV & Bird Flu Markets